REFERENCES
1. Roncalli M, Park YN, Di Tommaso L. Histopathological classification of hepatocellular carcinoma. Dig Liver Dis 2010;42 supp-S3:S228-34.
2. Bosman FT, Carneiro F, Hruban RH. WHO classification of tumours of the digestive system. 5th ed. Geneva: International agency for Research on Cancer; 2019. p. 229.
3. Ziol M, Pote N, Amaddeo G, Laurent A, Nault JC, et al. Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance. Hepatology 2018;68:103-12.
4. Okabe H, Yoshizumi T, Yamashita YI, Imai K, Hayashi H, et al. Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma. PLoS One 2018;13:e0203856.
5. Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular hepatocellular carcinoma: an aggressive subtype of hepatocellular carcinoma. Am J Surg Pathol 2019;43:943-8.
6. Rhee H, An C, Kim HY, Yoo JE, Park YN, et al. Hepatocellular carcinoma with irregular rim-like arterial phase hyperenhancement: more aggressive pathologic features. Liver Cancer 2019;8:24-40.
7. Calderaro J, Meunier L, Nguyen CT, Boubaya M, Caruso S, et al. ESM1 as a marker of macrotrabecular-massive hepatocellular carcinoma. Clin Cancer Res 2019;25:5859-65.
8. Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouze E, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017;67:727-38.
9. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52.
10. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010;34:1630-6.
11. Salomao M, Remotti H, Vaughan R, Siegel AB, Lefkowitch JH, et al. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 2012;43:737-46.
12. Tan PS, Nakagawa S, Goossens N, Venkatesh A, Huang T, et al. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int 2016;36:108-18.
13. Jain D, Nayak NC, Kumaran V, Saigal S. Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India. Arch Pathol Lab Med 2013;137:961-6.
14. Lee JS, Yoo JE, Kim H, Rhee H, Koh MJ, et al. Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma. PLoS One 2017;12:e0171922.
15. Yeh MM, Liu Y, Torbenson M. Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study. Hum Pathol 2015;46:1769-75.
16. Taniai M, Hashimoto E, Tobari M, Kodama K, Tokushige K, et al. Clinicopathological investigation of steatohepatitic hepatocellular carcinoma: a multicenter study using immunohistochemical analysis of adenoma-related markers. Hepatol Res 2018;48:947-55.
17. Ando S, Shibahara J, Hayashi A, Fukayama M. β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study. Virchows Arch 2015;467:535-42.
18. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69:7385-92.
19. Chan AW, Tong JH, Pan Y, Chan SL, Wong GL, et al. Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome. Am J Surg Pathol 2015;39:304-12.
20. Patel KR, Liu TC, Vaccharajani N, Chapman WC, Brunt EM. Characterization of inflammatory (lymphoepithelioma-like) hepatocellular carcinoma: a study of 8 cases. Arch Pathol Lab Med 2014;138:1193-202.
21. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998;27:407-14.
22. Chen CJ, Jeng LB, Huang SF. Lymphoepithelioma-like hepatocellular carcinoma. Chang Gung Med J 2007;30:172-7.
23. Cacciato Insilla A, Faviana P, Pollina LE, De Simone P, Coletti L, et al. Lymphoepithelioma-like hepatocellular carcinoma: case report and review of the literature. World J Gastroenterol 2015;21:10468-74.
24. Shinoda M, Kadota Y, Tsujikawa H, Masugi Y, Itano O, et al. Lymphoepithelioma-like hepatocellular carcinoma: a case report and a review of the literature. World J Surg Oncol 2013;11:97.
25. Park HS, Jang KY, Kim YK, Cho BH, Moon WS. Hepatocellular carcinoma with massive lymphoid infiltration: a regressing phenomenon? Pathol Res Pract 2009;205:648-52.
26. Si MW, Thorson JA, Lauwers GY, DalCin P, Furman J. Hepatocellular lymphoepithelioma-like carcinoma associated with epstein barr virus: a hitherto unrecognized entity. Diagn Mol Pathol 2004;13:183-9.
27. Shirabe K, Matsumata T, Maeda T, Sadanaga N, Kuwano H, et al. A long-term surviving patient with hepatocellular carcinoma including lymphocytes infiltration - a clinicopathological study. Hepatogastroenterology 1995;42:996-1001.
28. Emile JF, Adam R, Sebagh M, Marchadier E, Falissard B, et al. Hepatocellular carcinoma with lymphoid stroma: a tumour with good prognosis after liver transplantation. Histopathology 2000;37:523-9.
29. Wei J, Liu Q, Wang C, Yu S. Lymphoepithelioma-like hepatocellular carcinoma without Epstein-Barr virus infection: a case report and a review of the literature. Indian J Pathol Microbiol 2015;58:550-3.
30. An SL, Liu LG, Zheng YL, Rong WQ, Wu F, et al. Primary lymphoepithelioma-like hepatocellular carcinoma: report of a locally advanced case and review of literature. Int J Clin Exp Pathol 2015;8:3282-7.
31. Labgaa I, Stueck A, Ward SC. Lymphoepithelioma-like carcinoma in liver. Am J Pathol 2017;187:1438-44.
32. Chan AW, Zhang Z, Chong CC, Tin EK, Chow C, et al. Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma. J Pathol 2019;249:166-72.
33. Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res 2019;25:2116-26.
34. Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology 2016;64:2038-46.
35. Seok JY, Na DC, Woo HG, Roncalli M, Kwon SM, et al. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. Hepatology 2012;55:1776-86.
36. Farooq A, Merath K, Paredes AZ, Wu L, Tsilimigras DI, et al. Outcomes of patients with scirrhous hepatocellular carcinoma: insights from the national cancer database. J Gastrointest Surg 2019. Epub ahead of print
37. Lee JH, Choi MS, Gwak GY, Lee JH, Koh KC, et al. Clinicopathologic characteristics and long-term prognosis of scirrhous hepatocellular carcinoma. Dig Dis Sci 2012;57:1698-707.
38. Fujii T, Zen Y, Harada K, Niwa H, Masuda S, et al. Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma - human and cell culture study. Hum Pathol 2008;39:1185-96.
39. Okamura N, Yoshida M, Shibuya A, Sugiura H, Okayasu I, et al. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathol Int 2005;55:724-31.
40. Sugiki T, Yamamoto M, Taka K, Nakano M. Specific characteristics of scirrhous hepatocellular carcinoma. Hepatogastroenterology 2009;56:1086-9.
41. Kim SH, Lim HK, Lee WJ, Choi D, Park CK. Scirrhous hepatocellular carcinoma: comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection. Eur J Radiol 2009;69:123-30.
42. Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child 1956;91:168-86.
43. Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 1980;46:372-9.
44. Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, et al. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the surveillance, epidemiology, and end results database. United European Gastroenterol J 2013;1:351-7.
46. Choi WT, Ramachandran R, Kakar S. Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens. Hum Pathol 2017;63:1-13.
47. Mayo SC, Mavros MN, Nathan H, Cosgrove D, Herman JM, et al. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. J Am Coll Surg 2014;218:196-205.
48. Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014;343:1010-4.
49. Engelholm LH, Riaz A, Serra D, Dagnaes-Hansen F, Johansen JV, et al. CRISPR/Cas9 engineering of adult mouse liver demonstrates that the dnajb1-prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma. Gastroenterology 2017;153:1662-73.e10.
50. Kastenhuber ER, Lalazar G, Houlihan SL, Tschaharganeh DF, Baslan T, et al. DNAJB1-PRKACA fusion kinase interacts with beta-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci U S A 2017;114:13076-84.
51. Turnham RE, Smith FD, Kenerson HL, Omar MH, Golkowski M, et al. An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma. Elife 2019;8:e44187.
52. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 2018;68:113-26.
53. Gigante E, Ronot M, Bertin C, Ciolina M, Bouattour M, et al. Combining imaging and tumor biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma. Liver Int 2019; doi: 10.1111/liv.14261.
54. Mihara Y, Akiba J, Ogasawara S, Kondo R, Fukushima H, et al. Malic enzyme 1 is a potential marker of combined hepatocellular cholangiocarcinoma, subtype with stem-cell features, intermediate-cell type. Hepatol Res 2019;49:1066-75.
55. Garancini M, Goffredo P, Pagni F, Romano F, Roman S, et al. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transpl 2014;20:952-9.
56. He C, Zhang Y, Cai Z, Lin X. Competing risk analyses of overall survival and cancer-specific survival in patients with combined hepatocellular cholangiocarcinoma after surgery. BMC Cancer 2019;19:178.
57. De Vito C, Sarker D, Ross P, Heaton N, Quaglia A. Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series. Virchows Arch 2017;471:619-29.
58. Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, et al. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol 2019;248:164-78.
59. Bosman FT, Carneiro F, Hruban RH. WHO classification of tumours of the digestive system. Fourth edition ed. International agency for research on cancer; 2010.
60. Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, et al. Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017;66:952-61.
61. Balitzer D, Joseph NM, Ferrell L, Shafizadeh N, Jain D, et al. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma. Mod Pathol 2019;32:1486-94.
62. Audard V, Grimber G, Elie C, Radenen B, Audebourg A, et al. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol 2007;212:345-52.
63. Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol 2019;71:616-30.
